You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤醫藥(03320.HK):昆藥集團擬17.91億元收購華潤聖火51%權益

格隆匯6月11日丨華潤醫藥(03320.HK)發佈公吿,2024年6月7日,董事會已通過一項決議案並批准公司的非全資附屬公司華潤三九(000999.SZ)與昆藥集團(600422.SH)將訂立股權轉讓協議(“股權轉讓協議”),據此,華潤三九將同意出售,及昆藥將同意收購昆明華潤聖火藥業有限公司(“華潤聖火”)51%權益,總代價為人民幣17.91億元(“建議內部重組”)。

於本公吿日期,華潤聖火由華潤三九全資擁有並作為公司的非全資附屬公司入賬,由公司擁有約63.00%權益。建議內部重組完成後,預期公司於華潤聖火持有的權益將由約63.00%攤薄至約39.88%,而華潤聖火將仍為公司的非全資附屬公司。

公吿表示,建議內部重組有助落實公司“十四五”戰略規劃,優化產業鏈佈局,推動三七產業鏈高品質發展,進一步提升華潤三九在三七產業的影響力,並解決華潤聖火與昆藥的血塞通軟膠囊產品存在同業競爭的問題。公司相信建議內部重組將充分發揮華潤三九及昆藥各自於產品、銷售及分銷網絡、品牌、供應鏈等方面的優勢,並創造協同價值。與此同時,預計建議內部重組將有助於加快三七供應鏈的整合,打造行業標杆,進一步提升集團三七產品於市場滲透力及影響力,從而更好地推動以三七產品為代表的中醫藥產業鏈的高品質發展,為公司整體業績的增長奠定堅實的基礎。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account